Construction and application of the human glioblastoma cell line Y1203

doi:10.3969/j.issn.1006-7795.2023.05.005

Abstract

Abstract: Objective To establish a glioblastoma cell line, Y1203, with stem cell-like phenotypes for the study of tumor cell stemness maintenance and potential mechanisms of treatment resistance. Methods Y1203 cells were derived from tumor tissue obtained by recurrent resection in a 49-year-old female glioblastoma patient. Y1203 cells were used to establish patient-derived tumor xenograft (PDX) models both orthotopically and subcutaneously. Flow cytometry was applied to analyze the cell cycle distribution of different passages of Y1203 cells. Real-time quantitative polymerase chain reaction was performed to assess the expression of stem cell markers, including transcription factor SOX-2 (SOX2) and cluster of differentiation-44 (CD44). RNA-Seq was conducted to compare the expression profiles between Y1203 and U87 cells. Results The short tandem repeats (STR) analysis confirmed the homogeneity between Y1203 cells and the patient’s tumor tissue, and they were distinct from commonly used cell lines available in the ExPASy database. Genetic testing revealed isocitrate dehydrogenase 1 (IDH1) wild-type, telomerase reverse transcriptase (TERT) promoter mutation, B-Raf proto-oncogene (BRAF V600E) mutation, tumor protein p53 (TP53) mutation, and ATRX chromatin remodeler (ATRX) mutation. The human glioblastoma cell line Y1203 exhibited unlimited proliferation in vitro and thus orthotopic and subcutaneous glioblastoma models was successfully established. Compared to other glioma cell lines, Y1203 cells showed high expression of the tumor stem cell markers CD44 and SOX2, as well as significant enrichment of glioma stem cell-associated pathways. Conclusions The human glioblastoma cell line Y1203 shows low differentiation, high malignancy, and strong resistance to radiotherapy and chemotherapy, and it possesses glioblastoma stem cell characteristics. The establishment of Y1203 cell line provides an experimental basis for preclinical studies of glioblastoma.

Key words: glioblastoma, primary culture, stemness, patient derived tumor xenograft model

CLC Number:

Zheng Yi, Song Lairong, Xu Xiaoying, Wu Zhen, Li Xiaojie, Xie Lei, Chen Feng, Li Wenbin. Construction and application of the human glioblastoma cell line Y1203[J]. Journal of Capital Medical University, 2023, 44(5): 733-740.

References

［1］Peng Y, Chen F, Li S, et al. Tumor-associated macrophages as treatment targets in glioma［J］. Brain Sci Adv, 2020, 6(4):306-323.
［2］舒晓宏. 胶质母细胞瘤的治疗策略［J］. 大连医科大学学报,2020,42(6):481-486.
［3］杨帆, 张剑宁. 胶质母细胞瘤免疫治疗的研究现状及进展［J］. 中国微侵袭神经外科杂志,2020,25(8):376-378.
［4］Song L, Huo X, Li X, et al. SERPINF1 mediates tumor progression and stemness in glioma［J］. Genes (Basel),2023,14(3): 580.
［5］Akter F, Simon B, de Boer N L, et al. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities［J］. Biochim Biophys Acta Rev Cancer,2021,1875(1):188458.
［6］刘小珍, 郑智国, 凌志强. 肿瘤细胞原代培养与保存［J］. 中国肿瘤,2015,24(4):276-283.
［7］刘斌. 胶质瘤干细胞通过SOX2上调CD39介导免疫逃逸的功能及机制研究［D］: 苏州：苏州大学，2022.
［8］王雅宁. 基于胶质瘤干细胞性建立的替莫唑胺耐药临床预测模型及替莫唑胺耐药细胞系的构建和特征分析［D］. 北京：北京协和医学院，2022.
［9］庞龙, 张军峰, 刘博迪, 等. 脑胶质瘤干细胞分选方法研究进展［J］. 转化医学电子杂志,2018,5(7):17-22.
［10］张永辉, 昝向阳, 李敏, 等. 免疫磁珠法分选人脑胶质瘤干细胞的体外培养及鉴定［J］. 新疆医学,2012,42(6):17-20.
［11］周瑞婷, 何桂媛, 李文新, 等. 肿瘤干细胞的分选与培养［J］. 中国组织化学与细胞化学杂志,2022,31(4):401-406.
［12］Subramanian A, Tamayo P, Mootha V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles［J］. Proc Natl Acad Sci U S A, 2005,102 (43): 15545-15550.
［13］郑淑荣, 庞波, 柴睿超. 第五版《世界卫生组织中枢神经系统肿瘤分类指南》下成人胶质瘤诊断及预后［J］. 生物化学与生物物理进展,2022,49(11):2192-2198.
［14］Song L, Li X, Xu X, et al. Comprehensive analysis of the prognostic value and molecular function of CRNDE in glioma at bulk and single-cell levels［J］. Cell, 2022,11(22)：3669.
［15］Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions［J］. J Exp Clin Cancer Res, 2022, 41(1):142.
［16］郑诗凡, 马皎. 肿瘤干细胞代谢在肿瘤发展中作用的研究进展［J］. 上海交通大学学报(医学版),2022,42(6):825-832.
［17］李星霓. 肿瘤干细胞的研究进展及靶向治疗［J］. 内蒙古医学杂志,2022,54(6):707-709.
［18］陆翰杰, 秦艳茹. 肿瘤干细胞在肿瘤侵袭转移中的作用机制及功能相关信号通路研究进展［J］. 山东医药,2016,56(7):94-96.

[1]	Du Feng, Xu Rui, Zhao Mengran, Ji Xu, Su Jiayi, Qiu Yuting, Zhu Shengtao, Wu Jing, Li Peng, Zhang Shutian. The role and mechanism of SOX4 in Helicobacter pylori-mediated gastric mucosal epithelial dysplasia [J]. Journal of Capital Medical University, 2025, 46(4): 644-653.
[2]	Liu Juan, Zhang Zheng, Li Peng. Clinical characteristics of autoimmune gastritis patients complicated with early gastric cancer [J]. Journal of Capital Medical University, 2025, 46(4): 670-675.
[3]	Liu Honglei, Yang Yingliang, Li Ronghao, Zhu Congmin, Zhang Xu. Application of artificial intelligence in the study of cancer diagnosis and treatment research [J]. Journal of Capital Medical University, 2025, 46(3): 395-400.
[4]	Gao Tianbo, Ge Yang, An Guangyu, Yao Jiannan, Jiang Yuliang, Liu Heshu, Yan Rui. Abnormal O-glycosylation mediated by the deficiency of molecular chaperone Cosmc or T-synthase regulates the expression of miRNAs in colorectal cancer exosomes [J]. Journal of Capital Medical University, 2025, 46(3): 401-409.
[5]	Liu Xiaoqian, Sun Kai, Wang Xiaolin, Zhao Qianqian, Wu Xiaoxiao, Shen Fangqi, Chen Xi, Tian Chenxu, Wu Di, Song Chunhua, Xu HongXia, Cong Minghua, Shi Hanping, Jia Pingping. Comparison of the prognostic value of 15 nutritional/inflammatory indicators in postoperative cancer patients [J]. Journal of Capital Medical University, 2025, 46(3): 410-419.
[6]	Li Yawei, Yang Shoubo, Yin Shuo, Li Wenbin, Chen Feng. Clinical efficacy analysis of hetrombopag in the treatment of cancer therapy included thrombocytopenia for germ cell tumors [J]. Journal of Capital Medical University, 2025, 46(3): 420-426.
[7]	Wang Qinglian, Teng Ying, Qiao Wenying, Chen Jinglong, Ding Xiaoyan. Comparative analysis of efficacy and safety of different regimens in the treatment of AIDS-related Burkitt lymphoma: a single-center retrospective study [J]. Journal of Capital Medical University, 2025, 46(3): 427-435.
[8]	Wang Jingwen, Li Zhenjun, Lyu Liangcheng, Yao Xiaoyu, Ding Ning. B cell receptor signaling pathway and its therapeutic implications in B-cell lymphoma [J]. Journal of Capital Medical University, 2025, 46(3): 436-441.
[9]	Jiang Haiping, Yin Shuo, Li Shenglan, Li Wenbin. The progress in the role and application of neutrophils in glioma [J]. Journal of Capital Medical University, 2025, 46(3): 448-454.
[10]	Jing Fang, Jing Chao. Micro RNA-338-3p regulates proliferation, apoptosis, migration, and invasion of ovarian cancer cells through ERBB2 [J]. Journal of Capital Medical University, 2025, 46(3): 527-537.
[11]	Yang Peiyi, Duan Chao, Wang Shengcai, Jin Mei, Zhang Dawei, Fu Libing, Yu Tong, Liu Zhikai, Ma Xiaoli, Ni Xin, Su Yan. Analysis of clinical features and prognosis in pediatric malignant solid tumors of head and neck in single-center [J]. Journal of Capital Medical University, 2025, 46(3): 545-552.
[12]	Meng Lingzhao, Qu Xiaopeng, Tao Pengyu, Yang Fan, Rao Yuansheng, Wang Ru, Fang Jugao. Application value of low-temperature plasma bipolar forceps in thyroid cancer surgery [J]. Journal of Capital Medical University, 2025, 46(3): 553-558.
[13]	Shi Feng, ZhaoYanjie, Gao Ying, Song Qingkun. Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis [J]. Journal of Capital Medical University, 2025, 46(2): 210-215.
[14]	Fan Yunpeng, Xiong Tianyu, Yang Kun, Liu Zhanliang, Jin Song, Xie Ping, Niu Yinong. Prediction model for extraprostatic extension of prostate based on MRI and clinical indicators [J]. Journal of Capital Medical University, 2025, 46(2): 243-251.
[15]	Xiong Tianyu, Zhao Youquan, Xie Ping, Niu Yinong. Advances in research on the interaction mechanisms between androgen receptor and PI3K/AKT pathways in prostate cancer [J]. Journal of Capital Medical University, 2025, 46(2): 269-282.